| For Healthcare Professionals | Login to the Nplate® NEXUS Program |
 |
 |
 |
 |
 |
 |
 |
Ordering Nplate®
Answering Your Questions About the Nplate® (romiplostim) NEXUS Program
How Do I Order Nplate®?
Hospital and Institutional Ordering Nplate®
Once an institution and patient(s) are enrolled, an institution will receive an enrollment confirmation. This enrollment must be completed only once. Ordering and billing for Nplate® will occur through your primary wholesaler. A NEXUS Specialist will arrange shipment directly to the institution.
If desired, you may also order a small safety stock for emergency only. This safety stock can be ordered only by calling 1-877-NPLATE1 (1-877-675-2831).
Prescribing Nplate®
When a healthcare provider enrolled in the Nplate® NEXUS Program identifies and prescribes Nplate® to an appropriate patient, a designated hospital staff member will check with the Nplate® NEXUS Program to verify that the patient was previously enrolled in the program.
An Nplate® NEXUS Program Patient Enrollment Form must be completed for any new patient.
Record Keeping
Enrolled institutions will be required to maintain drug accountability and reconciliation records.This may include, at minimum, the following information:
- Once you and your patient are enrolled in the Nplate® NEXUS Program, place an order with your preferred distributor, or call 1-877-NPLATE1 (1-877-675-2831), and a NEXUS Specialist will facilitate your order through your normal distributor.
- The NEXUS Specialist confirms that you are enrolled in the program and are treating enrolled patients.
- Your order will be forwarded to the Nplate® NEXUS Program, where a NEXUS Specialist will call your office to arrange shipment.
- If desired, you may also order a small safety stock for emergency only. This safety stock can be ordered only by calling 1-877-NPLATE1 (1-877-675-2831).
- Nplate® usually ships within 48 hours in an insulated cold-shipping container to your office.
Once an institution and patient(s) are enrolled, an institution will receive an enrollment confirmation. This enrollment must be completed only once. Ordering and billing for Nplate® will occur through your primary wholesaler. A NEXUS Specialist will arrange shipment directly to the institution.
If desired, you may also order a small safety stock for emergency only. This safety stock can be ordered only by calling 1-877-NPLATE1 (1-877-675-2831).
When a healthcare provider enrolled in the Nplate® NEXUS Program identifies and prescribes Nplate® to an appropriate patient, a designated hospital staff member will check with the Nplate® NEXUS Program to verify that the patient was previously enrolled in the program.
An Nplate® NEXUS Program Patient Enrollment Form must be completed for any new patient.
Enrolled institutions will be required to maintain drug accountability and reconciliation records.This may include, at minimum, the following information:
- Name and unique identification number of enrolled prescribing healthcare provider
- Unique identifier (program ID number, name, date of birth, address) of the enrolled patient receiving Nplate®
- Date of each Nplate® order (including number of vials ordered and vial size)
- Overall inventory for the set period of time including the total number of vials ordered,
dispensed, and in stock
Nplate® is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins
or splenectomy.
Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.
IMPORTANT SAFETY INFORMATION
Serious adverse reactions associated with Nplate® in clinical studies were bone marrow reticulin deposition
and worsening thrombocytopenia after Nplate® discontinuation. Additional risks include Bone Marrow Fibrosis, Thrombotic/Thromboembolic Complications, Lack or Loss of Response to Nplate®, and Hematological Malignancies and Progression of Malignancy in Patients with a Pre-existing Hematological Malignancy or Myelodysplastic Syndrome (MDS).
Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.
Nplate® is available only through a restricted distribution program called Nplate® NEXUS (Network of Experts Understanding and Supporting Nplate® and Patients) Program.
In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction.
Home |
About Nplate® NEXUS |
Enrollment |
Ordering Nplate®
Support & Follow-Up | Risk Monitoring | Resources | Terms of Use and Privacy Policy
Support & Follow-Up | Risk Monitoring | Resources | Terms of Use and Privacy Policy
